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Differential antibody responses to gliadin-derived indigestible
peptides in patients with schizophrenia
RT McLean1, P Wilson2, D St Clair3, CJ Mustard1 and J Wei1
Gluten consumption has previously been implicated in the development of schizophrenia while an immunological link between
gluten and schizophrenia was established by the detection of circulating antibodies against gliadin, a major component of wheat
gluten. Several studies have reported an increase in circulating antibodies against native gliadin molecules that are unlikely to
survive degradation in the digestive system. In this study, therefore, we measured plasma immunoglobulin G (IgG) and IgA
antibodies against indigestible gliadin-derived peptide antigens using an in-house enzyme-linked immunosorbent assay (ELISA)
among 169 patients with schizophrenia and 236 control subjects. We also examined the plasma levels of IgG and IgA antibodies
against the mixture of native gliadins using commercially available ELISA kits. The results showed that patients with schizophrenia
had the increased levels of plasma IgG against the γ-gliadin-derived fragment, namely AAQ6C, but decreased levels of plasma IgG
against the α- and γ3-gliadin-derived antigens, as compared with control subjects. This study also demonstrated a uniform decrease
in plasma IgA antibodies against gliadin-derived antigens. There was no signiﬁcant difference in the levels of plasma antibodies
against native gliadins between the patient group and the control group. Of eight gliadin-derived antigens tested, four showed a
sensitivity of420% against the speciﬁcity of ⩾ 95% for detection of their corresponding antibodies in plasma. These four tests may
thus have a potential to serve as biomarkers for the identiﬁcation of schizophrenia subgroups that may need an alternative therapy
or precision treatment. Further investigation with clinical trials should be carried out to explore this possibility.
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INTRODUCTION
Schizophrenia is a complex psychiatric disorder, demonstrating
heterogeneity in clinical presentation with a combination of
positive, negative and cognitive symptoms.1 What causes schizo-
phrenia remains unknown but alterations of neuronal commu-
nication are believed to underlie the pathophysiology of the
illness.2–5 Owing to the diversity of clinical presentation,
differences in treatment response and variable epidemiology, it
is likely that multifactorial mechanisms contribute to a spectrum
of schizophrenic illnesses.6–8
A role of gluten consumption in the development of schizo-
phrenia was initially proposed based on the observation of a
positive correlation between national wheat imports and hospital
admissions for schizophrenia.9 Although the outcomes have been
inconsistent, studies have attempted to examine the efﬁcacy of
gluten-free diets in the treatment of schizophrenia, demonstrating
improvement of clinical scales and earlier recovery in some
patients treated with gluten-free diets.10–13 Case studies in the
literature have further demonstrated the induction of psychiatric
and schizophrenia-like symptoms in response to gluten challenge
and the resolution of these symptoms with gluten-free diets.14,15
A mechanism by which gluten consumption may have a role in
the development of schizophrenia has yet to be demonstrated. A
number of immunological alterations have been found to be
associated with schizophrenia, including an increase in pro-
inﬂammatory cytokines and microglia activation.16–19 In addition,
an increase in immunoglobulins (Ig) G and A classes against native
gliadin, a major component of wheat gluten, was previously
observed in a proportion of patients with schizophrenia.12,20–25
The initiation of Ig production relies upon the recognition and
presentation of antigens by the human leukocyte antigen class II
(HLA-II) molecules. Genome-wide association studies revealed that
the loci most strongly associated with schizophrenia resided in the
HLA region.26–28
The epitopes recognized by anti-gliadin antibodies (AGAs)
detected in schizophrenia may be different from those identiﬁed
in the gluten-sensitive enteropathy coeliac disease (CD). Of
schizophrenia patients who were positive for AGA IgA, only
3.8% were positive for IgA against CD-speciﬁc gliadin-derived
epitopes, compared with 12.2% of control subjects.22,29 Further-
more, patients pre-selected for high AGA levels did not display
high levels of CD-speciﬁc serological markers, such as plasma
antibodies against tissue transglutaminase.30 Previous studies
suggested that the pathogenic gluten fragments for CD were
mainly derived from α2-gliadin and γ5-gliadin, whereas immune
reactivity to γ3-gliadin and its homologous sequence (NCBI
accession AAQ6387) was associated with schizophrenia.30–32
To date, all the tests for circulating AGAs in schizophrenia have
been developed with mixtures of full-length native gliadins
consisting of ~ 300 amino acid residues. Such a test would detect
antibodies against not only linear epitopes but also conforma-
tional epitopes that are unlikely to survive digestion in the gut. In
this study, we measured plasma levels of IgG and IgA against
indigestible peptide fragments derived from γ- and α-gliadins,
which harbour HLA-II restricted epitopes, with an in-house
enzyme-linked immunosorbent assay (ELISA) in individuals with
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schizophrenia and healthy controls. We also tested circulating
AGAs in our case–control samples using commercially available
ELISA kits.
MATERIALS AND METHODS
Subjects
A total of 405 archived plasma samples collected from patients with
schizophrenia (n=169, 132 males and 37 females, aged 42.0 ± 13.3 years)
and control subjects (n= 236, 159 males and 77 females, aged 44.7 ± 12.5
years), were used to examine the levels of circulating antibodies against
gliadin-derived peptide antigens. These samples were collected through
the University of Aberdeen in the period between 2003 and 2008, and had
been stored long-term at − 80 °C without defrosting until they were
aliquoted for antibody testing. All patients were diagnosed as having
schizophrenia based on the DSM-IV criteria. Control subjects were
recruited from a local population in Scotland and screened for psychiatric
disorders as described previously.26 No case samples were reported to
have CD. Both case and control samples were collected in the same period
and stored under the same conditions. Antipsychotic drugs used by
schizophrenia patients at the time of sampling are listed in Supplementary
Table 1, with 128 patients taking a single antipsychotic drug, 14 taking
more than one drug and 27 without medication details. All the subjects
were classiﬁed as British Caucasian and they all gave informed written
consent to donate blood samples for research of the pathophysiology of
schizophrenia. This study was approved by a local ethics committee and
conformed to the provisions of the Declaration of Helsinki.
Antigen selection
Based on previous literature suggesting immune reactivity against the γ-
gliadins in schizophrenia and α-gliadins in CD,30,32 sequences of interest
were retrieved from the NCBI protein database (http://www.ncbi.nlm.nih.
gov/protein). The sequences were analysed in silico to determine
indigestible fragments using PeptideCutter software.33 The linear peptide
antigens used in this study were selected on the basis of the presence of
computationally predicted HLA-II binding epitopes.34,35 The resulting
sequences were HLA-II restricted and did not contain cutting sites for
pepsin, trypsin and chymotrypsin (Table 1). A 29-mer peptide (H-
HAQLEGRLHDLPGCPREVQRGFAATLVTN-OH) derived from a maize protein
sequence (NCBI accession 1BFA_A) was used as control peptide for
nonspeciﬁc binding. All peptide antigens were synthesized by solid-phase
chemistry with a purity of 495% (Severn Biotech, Worcestershire, UK).
In-house ELISA for antibodies against gliadin-derived antigens
Each synthetic peptide was dissolved in 67% acetic acid into a 5 mg ml− 1
stock solution and stored long-term at − 20 °C. The working solution was
made by diluting the stock solution with phosphate-buffered saline-based
coating buffer (P4417, Sigma-Aldrich, Dorset, UK) to 10 μg ml− 1 for both
gliadin-derived antigens and the control antigen; 100 μl working solution
was added to each well on Nunc-Immuno Maxisorp 96-well microtiter
plates (DIS-971-030 J, Thermo Fisher Scientiﬁc, Loughborough, UK). Each
plate was coated with two gliadin-derived antigens and the control
peptide. After incubation at 4 °C overnight, the plate was washed three
times with wash buffer (T9039, Sigma-Aldrich); 100 μl plasma samples were
diluted 1:100 in assay buffer (phosphate-buffered saline containing 1.5%
bovine serum albumin) for IgA assay and 1:150 for IgG assay, and were
added to each sample well. The negative control (NC) wells contained
100 μl assay buffer only. Following incubation for 1.5 h at room
temperature, the plate underwent additional washing as described above,
and was then incubated for 1.0 h with 100 μl of peroxidase-conjugated
goat antibodies either to human IgG (ab98624, Abcam, Cambridge, UK) or
to human IgA (A0295, Sigma-Aldrich) diluted 1:30 000–50 000 in assay
buffer. The plate underwent additional washing steps; colour development
was then initiated by adding 100 μl Stabilized Chromogen (SB02, Life
Technologies, Glasgow, UK) and terminated 20 min later with 50 μl Stop
Solution (SS04, Life Technologies). The resulting colour change was
measured as optical density (OD) at 450 nm with a reference wavelength
of 620 nm on a microplate reader. An inter-assay deviation was estimated
using quality control samples, which were pooled from 20 to 30 healthy
control samples, tested on every 96-well plate, and expressed as a
coefﬁcient of variation (CV%) to represent the reproducibility of the in-
house ELISA.
Each sample was tested in duplicate. To reduce the interference from
nonspeciﬁc signals due to the passive absorption of various antibodies in
plasma to 96-well microplates, a speciﬁc binding index was introduced to
express the relative levels of circulating antibodies against gliadin-derived
antigen (AGDA). The speciﬁc binding index (SBI) was calculated as follows:
SBI = [ODgliadin−ODNC]/[ODmaize−ODNC].
Testing of AGAs
The plasma AGAs were assayed using commercially available kits for both
IgG and IgA against the full-length native gliadin molecules (Omega
Diagnostics, Cambridge, UK). All the assays were performed according to
the manufacturer’s instructions (http://www.omegadiagnostics.com/). The
OD reading of each sample was normalized to the mean OD reading of
four-well standards provided for qualitative testing.
Data analysis
The Kolmogorov–Smirnov test failed to show a normal distribution of
AGDA levels in both the patient and control groups (Supplementary Table
2), so the Mann–Whitney U-test was applied to examine the differences in
AGDA levels and AGA levels between the two groups. Owing to multiple
testing, the Bonferroni correction was applied to reduce the type I errors
and Po0.006 was considered to be statistically signiﬁcant. The receiver
operating characteristic curve analysis was applied to calculate the area
under the receiver operating characteristic curve (AUC) with calculation of
the ELISA sensitivity against a speciﬁcity of ⩾ 95%. Linear regression was
applied to examine which antipsychotic drugs might affect the secretion of
circulating AGDA antibodies. In this analysis, the antibody levels were used
as a dependent variable, and medication, age and sex were used as the
independent variables; Fisher’s combining probability test was applied to
determine combined P-values based on nine drug-group tests for altered
levels of plasma antibodies reacting with each antigen.36 Multivariate
linear regression was applied to examine the correlations between AGA
IgG levels and AGDA IgG levels.
Table 1. Sequence information of peptide antigens used for the in-house ELISA
NCBI accession (antigen) Sequence Position (aa) Native molecule
CAB76957 (AL1G1) KCSFQSSQQNPQAQGSVQPQQLPQ 205–226 α1-Gliadin
CAB76964 (AL2G1) CPFRPQQPYPQSQPQYSQPQQPISQK 88–111 α2-Gliadin
CAB76964 (AL2G2) KNVYIPPYCTIAPVGIFGTNYR 270–290 α2-Gliadin
AAQ6387 (AAQ6A) CHFIQPQQPFPQQPQQSFPQQQPSLIK 59–72
110–119
γ-Gliadin
AAQ6387 (AAQ6B) CHSIIMQQEQQEQRQGVQILVPLSQK 185–208 γ-Gliadin
AAQ6387 (AAQ6C) HPKCSIMRAPFASIVAGIGGQYRD 253–274 γ-Gliadin
ABO37962 (ABO3a) KATTIATANMQVDPSGQVQWPQQQPFRC 13–38 γ3-Gliadin
ABO37962 (ABO3b) KYVRPDCSTINAPFASIVAGISGQH 263–285 γ3-Gliadin
Abbreviation: ELISA, enzyme-linked immunosorbent assay. Peptide sequences were selected from in silico analysis of by PeptideCutter to determine
indigestible fragments of 49 amino acid residuals in length, which may have potential antigenicity.
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RESULTS
Reproducibility of the in-house ELISA
This in-house ELISA had a good reproducibility, in which the inter-
assay deviations ranged from 4.6 to 7.5% for AGDA IgA assay and
from 9.4 to 16.3% for AGDA IgG assay (Supplementary Table 3).
Levels of circulating AGDA antibodies
As shown in Table 2, patients with schizophrenia had signiﬁcantly
higher levels of plasma anti-AAQ6C IgG than control subjects
(Z=− 4.65, Po0.001), but signiﬁcantly lower levels of IgG
antibodies against AL1G1 (Z=− 4.65, Po0.001) AL2G1 (Z=− 8.72,
Po0.001), AL2G2 (Z=− 6.01, Po0.001), ABO3a (Z= –6.37,
Po0.001) and ABO3b (Z=− 5.32, Po0.001). The circulating AGDA
IgA levels were all signiﬁcantly lower in the patient group than the
control group (Table 3). Exclusion analysis revealed that the male
patients were more likely to contribute to altered AGDA levels in
the circulation than the female patients (Supplementary Tables 4
and 5).
Levels of circulating AGAs
As shown in Table 4, there was no signiﬁcant difference in plasma
AGA IgG levels between the patient group and the control group
(Z=− 0.31, P= 0.757). Consistent with the direction of previous
studies, a nonsigniﬁcant increase in plasma AGA IgA levels was
observed in patients with schizophrenia (Z=− 0.22, P= 0.825).
Receiver operating characteristic curve analysis
Receiver operating characteristic curve analysis revealed that at a
speciﬁcity of ⩾ 95% (Table 5), ﬁve assays had a sensitivity of
420%, including anti-AAQ6C IgG assay (20.4%, AUC= 0.65), anti-
AL2G1 IgG assay (30.7%, AUC= 0.76), anti-AL2G2 IgA assay (20.2%,
AUC= 0.71), anti-ABO3a IgA assay (40.0%, AUC= 0.87) and anti-
ABOb IgA assay (35.8%, AUC= 0.81).
Effects of antipsychotic medication on antibody secretion
Linear regression analysis demonstrated that quetiapine was the
only antipsychotic drug signiﬁcantly associated with elevated
levels of IgG against AAQ6B (adjusted r2 = 0.065, t= 3.13,
P= 0.002), and eight other antipsychotic drugs did not show a
signiﬁcant association with AGDA IgG levels (Supplementary Table
6); the secretion of AGDA IgA antibodies and AGAs did not appear
to be inﬂuenced by antipsychotic medication (Supplementary
Tables 7 and 8). Fisher’s combining probability test revealed that
none of the nine antipsychotic drugs listed in Supplementary
Table 1 was signiﬁcantly associated with the levels of total
antibodies against each gliadin-derived antigen in this study
(Supplementary Tables 6 and 7).
Correlation between AGDA antibodies and AGAs
Multivariate linear regression analysis revealed a signiﬁcant
correlation between AGA IgG levels and AGDA IgG levels
(Supplementary Tables 9 and 10), in which anti-AL1G1 IgG level
was the best predictor of AGA IgG level out of all AGDA IgG
antibodies tested in the control group (Standardized β= 0.20,
P= 0.004), while anti-AAQ6C IgG level was the most signiﬁcantly
correlated to AGA IgG levels in the patient group (Standardized
β= 0.17, P= 0.037).
DISCUSSION
This study was undertaken to compare circulating AGDA levels
between patients with schizophrenia and healthy controls. The
levels of plasma IgG against γ-gliadin-derived antigen AAQ6C
were elevated in patients with schizophrenia when compared
with healthy controls (Table 2). It is possible that an immune
response to the AAQ6C antigen is associated with a subgroup of
schizophrenia patients although additional factors, such as their
access to the central nervous system, are likely to determine the
potential pathological activities of these antibodies in patients
with schizophrenia. It has previously been demonstrated that α2-
gliadin-derived peptides may not be immunogenic in schizo-
phrenia but are likely to be immunogenic in CD patients.30 A
genome-wide association study revealed that the DQA1*0501/
DQB1*0201 alleles that encode HLA-DQ2.5 molecules conferring a
Table 2. Levels of circulating IgG against gliadin-derived peptide
antigens
Antigen Control (n) Case (n) Z P
Mean ± s.d. Mean ± s.d.
AL1G1 0.94 (218) 0.20 0.89 (169) 0.18 − 4.65 o0.001
AL2G1 1.11 (224) 0.30 0.94 (167) 0.21 − 8.72 o0.001
AL2G2 1.28 (224) 0.26 1.19 (167) 0.21 − 6.01 o0.001
AAQ6A 1.50 (224) 1.68 1.64 (167) 1.20 − 1.19 0.264
AAQ6B 1.16 (222) 0.31 1.36 (167) 0.97 − 2.72 0.007
AAQ6C 1.14 (223) 0.29 1.22 (167) 0.26 − 4.65 o0.001
ABO3a 1.02 (211) 0.34 0.91 (161) 0.19 − 6.37 o0.001
ABO3b 1.01 (211) 0.13 0.95 (161) 0.12 − 5.32 o0.001
Mann–Whitney U-test was used to test the differences in plasma against
gliadin-derived antigen (AGDA) immunoglobulin G (IgG) levels between
healthy controls and patients with schizophrenia. Based on the Bonferroni
correction, Po0.006 was set as being statistically signiﬁcant.
Table 3. Levels of circulating IgA against gliadin-derived peptide
antigens
Antigen Control (n) Case (n) Z P
Mean ± s.d. Mean ± s.d.
AL1G1 0.83 (222) 0.07 0.81 (166) 0.09 − 4.17 o0.001
AL2G1 0.95 (222) 0.11 0.91 (166) 0.11 − 7.09 o0.001
AL2G2 1.00 (222) 0.04 0.96 (166) 0.06 − 7.20 o0.001
AAQ6A 1.07 (224) 0.21 0.98 (167) 0.23 − 7.28 o0.001
AAQ6B 0.93 (224) 0.13 0.90 (167) 0.13 − 3.02 0.003
AAQ6C 1.02 (222) 0.08 0.96 (166) 0.08 − 6.82 o0.001
ABO3a 1.05 (221) 0.16 0.94 (166) 0.08 − 12.51 o0.001
ABO3b 0.92 (221) 0.04 0.87 (166) 0.05 − 10.29 o0.001
Mann–Whitney U-test was used to test the differences in plasma against
gliadin-derived antigen (AGDA) immunoglobulin A (IgA) levels between
healthy controls and patients with schizophrenia. Based on the Bonferroni
correction, Po0.006 was set as being statistically signiﬁcant.
Table 4. Levels of plasma antibodies against native gliadins
Antigen Control (n) Case (n) Z P
Mean ± s.d. Mean ± s.d.
AGA IgG 0.64 (226) 0.54 0.65 (168) 0.52 − 0.31 0.757
AGA IgA 0.78 (223) 0.49 0.84 (167) 0.72 −0.22 0.825
Mann–Whitney U-test was used to compare the differences in plasma anti-
gliadin antibody (AGA) levels between healthy controls and patients with
schizophrenia. Po0.05 was set as being statistically signiﬁcant.
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major risk of CD, were signiﬁcantly less prevalent in schizophrenia
cases than healthy controls;26 therefore, the decreased levels of
circulating antibodies against α-gliadin-derived antigens may
partially result from the low frequency of the DQA1*0501/
DQB1*0201 alleles in the patient group.
Against all gliadin-derived peptide fragments tested, circulating
levels of all AGDA IgA antibodies were signiﬁcantly lower in
schizophrenia patients than healthy controls (Table 3). Although
not uniformly observed, a decrease in global IgA levels has been
previously measured in patients with schizophrenia and therefore
the decrease in AGDA IgA levels may be related to this
observation.37,38 The role of gastrointestinal inﬂammation has
recently gained attention in the development of schizophrenia as
well as in neurological and psychiatric conditions more
generally.39 A previous study that examined the markers of gut-
inﬂammation in non-IgE-mediated cow’s milk allergy demon-
strated that infants with such an allergy had a signiﬁcant decrease
in serum IgA in response to food challenge accompanied by a
decrease in a subclass of IgG speciﬁc for α-casein and an increase
in gastrointestinal inﬂammation.40 There is also evidence that
circulating IgA has an anti-inﬂammatory role41 and decreased IgA
levels are commonly found in patients with autoimmune
disease.42 Accordingly, decreased AGDA IgA levels observed in
the present study may reﬂect dysfunction of immune-regulation
and inﬂammatory processes possibly in the gastrointestinal tract.
Several studies, including a meta-analysis, have suggested an
association between increased AGAs for native gliadins and
schizophrenia.12,20–23,25 However, the present study failed to show
a signiﬁcant increase in either AGA IgG levels or AGA IgA levels,
although a nonsigniﬁcant increase in AGA IgA levels was observed
in patients with schizophrenia (Table 4). All native gliadin
molecules consist of ~ 300 amino acid residues and are unlikely
to survive degradation in the digestive system. It is possible that
multiple AGAs recognizing distinct epitopes are different between
the case group and the control group. Regression analysis
examining the correlation between the AGA IgG and the AGDA
IgG suggests that anti-AAQ6C IgG is the most predictive of AGA
IgG levels in patients with schizophrenia and that anti-AL2G1 IgG
is the most predictive of AGA IgG levels in control subjects,
suggesting the existence of differential epitopes bound to AGA
antibodies in schizophrenia (Supplementary Tables 9 and 10).
Antipsychotic medication is the ﬁrst-line treatment of schizo-
phrenia but only 50–60% patients show a good response to
antipsychotic drugs.7 Consequently, there is an urgent need to
identify speciﬁc biomarkers for precision treatment of the disease.
Of eight gliadin-derived antigens tested in this study, four showed
a sensitivity of 420% for the detection of their corresponding
antibodies in plasma (Table 5). These four tests may thus have a
potential to serve as biomarkers for identiﬁcation of a gluten-
related subgroup of schizophrenia, which may be useful for the
development of precision treatments.
Owing to the nature of sample collection and the correspond-
ing database information, it was not possible to fully control the
potential confounding effects of lifestyle factors, such as alcohol
consumption, tobacco use and diets, on the outcomes measured
in these case–control samples. Although healthy control subjects
were screened for psychiatric illness, there was no additional
medical information available and therefore other confounding
factors cannot be excluded. Furthermore, the clinical information
for patients did not contain consistent reference to clinical
subtypes of schizophrenia and so clinical or symptomatic
associations for circulating AGDA levels cannot be analysed in
this cohort. The lack of antipsychotic-free or drug-naive patients
and incomplete medication histories mean that a potential effect
of antipsychotic medication on the secretion of anti-gluten
antibodies cannot be ruled out, which is a major limitation of
this study. Fisher’s combining probability test, however, failed to
detect a signiﬁcant association between antipsychotic medication
and circulating anti-gliadin antibody levels (Supplementary Tables
6–8), suggesting that antipsychotic drugs may not signiﬁcantly
affect the secretion of anti-gluten antibodies. Finally, there is an
overrepresentation of male subjects in the case group when
compared with the control group; the small sample size in females
may have underpowered the test for gender differences in
antibody secretion.
In summary, this preliminary study demonstrates that altered
AGDA levels in the circulation are associated with schizophrenia
and could serve as biomarkers for the identiﬁcation of a
schizophrenia subgroup that may need an alternative therapy or
precision treatment. Further investigations with clinical trials
should be carried out to explore this possibility.
Table 5. ROC curve analysis of plasma anti-gluten antibodies in schizophrenia
Antibody test Speciﬁcity (%) Sensitivity (%) AUC s.e. P 95% CI
IgG
AAQ6A 95.1 6.0 0.54 0.03 0.243 0.48–0.53
AAQ6B 95.0 8.4 0.58 0.03 0.008 0.52–0.64
AAQ6C 95.1 20.4 0.65 0.03 o0.001 0.59–0.70
AL1G1 95.0 4.2 0.64 0.03 o0.001 0.58–0.70
AL2G1 95.1 30.7 0.76 0.03 o0.001 0.71–0.81
AL2G2 95.1 15.0 0.68 0.03 o0.001 0.63–0.73
ABO3a 95.3 13.8 0.69 0.03 o0.001 0.64–0.75
ABO3b 95.3 7.5 0.66 0.03 o0.001 0.61–0.72
Gliadin 95.1 5.4 0.51 0.03 0.757 0.43–0.55
IgA
AAQ6A 95.1 18.0 0.72 0.03 o0.001 0.67–0.77
AAQ6B 95.1 6.6 0.59 0.03 0.002 0.53–0.65
AAQ6C 95.0 16.4 0.70 0.03 o0.001 0.65–0.75
AL1G1 95.0 10.9 0.62 0.03 o0.001 0.57–0.68
AL2G1 95.0 14.5 0.71 0.03 o0.001 0.66–0.76
AL2G2 95.0 20.2 0.71 0.03 o0.001 0.66–0.76
ABO3a 95.0 40.0 0.87 0.02 o0.001 0.83–0.91
ABO3b 95.0 35.8 0.81 0.02 o0.001 0.76–0.85
Gliadin 95.1 6.6 0.49 0.03 0.825 0.44–0.55
Abbreviations: AUC, area under the ROC curve; CI, conﬁdence interval; Ig, immunoglobulin; ROC, receiver operating characteristic.
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